Clinical Trial Tests Self-Injection That Improves Myasthenia Gravis From First Week

A new clinical trial demonstrates that a self-injection treatment can significantly improve myasthenia gravis symptoms within the first week of use. Myasthenia gravis is a neuromuscular disorder that causes progressive muscle weakness, making everyday activities like speaking, chewing, swallowing, and walking increasingly difficult as the day progresses. This breakthrough therapy offers new hope for patients who struggle with the debilitating effects of this chronic autoimmune condition. The rapid improvement observed in early trials could transform treatment options for myasthenia gravis patients who currently have limited therapeutic choices.